Form 8-K · Current report
Albemarle Corporation 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0000915913
- Accession no.
- 0000915913-26-000128
Summary
Albemarle reported third-quarter 2026 net sales of $1.6 billion, up 19%, and adjusted EBITDA of $646 million, up 186%, while raising its full-year Specialties adjusted EBITDA outlook to $350–375 million and cutting its capital expenditure forecast to $300–350 million. CEO Kent Masters said global lithium demand rose 48% year-to-date through August, driven by electric vehicles and energy storage.
Key points
- Net income attributable to Albemarle was $297 million, or $2.15 per diluted share; adjusted net income was $354 million, or $2.58 per diluted share.
- Energy Storage net sales rose 58% to $1.1 billion on higher realized lithium pricing, while segment sales volume fell 18.8% year over year.
- A fire on June 9 delayed the ramp of Talison's Chemical Grade Plant 3; full-year 2026 sales volumes are expected at 225–235 kilotons lithium carbonate equivalent.
- Albemarle will hold a teleconference on November 5, 2026 to discuss the quarter's results.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On November 4, 2026, Albemarle Corporation (the “Company”) issued a press release reporting its results for the third quarter ended September 30, 2026. A copy of this release is being furnished as Exhibit 99.1 hereto and incorporated herein by reference. In addition, on November 5, 2026, the Company will hold a teleconference for analysts and media to discuss results for the third quarter ended September 30, 2026. The teleconference will be webcast on the Company’s website at www.albemarle.com. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.